

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0449

TITLE: Modulation of Postmenopausal Steroid Hormone Levels by  
Phytoestrogens and Correlation with Breast Proliferative  
Activity and Menopausal Symptoms

PRINCIPAL INVESTIGATOR: Melanie R. Palomares, M.D.  
Julie R. Galow, M.D.

CONTRACTING ORGANIZATION: University of Washington  
Seattle, Washington 98105-6692

REPORT DATE: July 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 01 -30 Jun 02)
----------------------------------	-----------------------------	--

4. TITLE AND SUBTITLE Modulation of Postmenopausal Steroid Hormone Levels by Phytoestrogens and Correlation with Breast Proliferative Activity and Menopausal Symptoms	5. FUNDING NUMBERS DAMD17-01-1-0449
---	--

6. AUTHOR(S) Melanie R. Palomares, M.D. Julie R. Gralow, M.D.
---

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Washington Seattle, Washington 98105-6692  E-Mail: mpalomar@fhcrc.org	8. PERFORMING ORGANIZATION REPORT NUMBER
--	--

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
---	--

20030226 070

11. SUPPLEMENTARY NOTES
-------------------------

12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited	12b. DISTRIBUTION CODE
---	------------------------

**13. ABSTRACT (Maximum 200 Words)**  
To evaluate the effect of a phytoestrogen supplement on steroid hormones and their target tissues, 60 disease-free postmenopausal breast cancer survivors are being randomized to either 100mg/d isoflavone tablets or placebo for one year. Hormone levels are measured at baseline, 6 months, and one year. Changes in menopausal symptoms, vaginal maturation, and breast epithelial proliferation are also being measured.

The trial was opened to accrual in June 2001. As of June 2002, 631 breast cancer patients had been screened through the Seattle Cancer Care Alliance. We received 56 additional self or clinician referrals. From both groups, 467 were found to be ineligible, 52 refused participation. The number one reason for ineligibility at our institution is stage (75%). Of the eight women who stated their primary reason for refusal, the most common reasons have been complaints of invasiveness of the trial (15%) and unwillingness to take phytoestrogen supplements (31%).

In order to increase recruitment yield, a mechanism to see patients who receive their oncologic care outside the sponsoring institution was developed, and a community outreach campaign begun. In the past month, 4 more women have been randomized. We expect to have full data on 8 subjects and mid-intervention data on at least 6 subjects by the time of the next annual report.

14. SUBJECT TERMS phytoestrogens, soy survivorship	15. NUMBER OF PAGES 8
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
---	--	---	---

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>5</b>
<b>Reportable Outcomes.....</b>	<b>6</b>
<b>Conclusions.....</b>	<b>6</b>
<b>References.....</b>	<b>6</b>
<b>Appendices.....</b>	<b>8</b>

## **Modulation of Postmenopausal Steroid Hormone Levels by Phytoestrogens and Correlation with Breast Proliferative Activity and Menopausal Symptoms**

Melanie R. Palomares, MD and Julie R. Gralow, MD

### **Introduction:**

Overall 5-year survival from breast cancer is now 85%, and most surviving women are postmenopausal. Nearly half of postmenopausal American women take estrogen replacement to relieve hot flashes and other symptoms of menopause, but this is contraindicated in women with breast cancer. Phytoestrogen supplements can be used as an alternative, but their effect on the risk of cancer recurrence is unknown. Given the mixed results of phytoestrogen studies regarding breast cell stimulation and inhibition in the medical literature, the effect of phytoestrogens on postmenopausal breast cancer survivors is unclear. To evaluate the effect of a phytoestrogen supplement on steroid hormones and breast epithelial proliferation, 60 disease-free, post-therapy, postmenopausal women with in-situ or early invasive (St. 0-II) breast cancer are being randomized to either 100mg/d isoflavone tablets or placebo for one year. Hormone levels are measured at baseline, 6 months, and one year. Changes in menopausal symptoms and vaginal maturation are also being measured.

### **Body:**

#### **Task 1: Study Preparation - completed**

##### **a. Development of materials – completed**

Brochures, flyers, advertisements, web pages, cover letters, as well as data collection forms and study charts were developed. Screening and study data databases were designed and tested for use as well. Both active and placebo tablets were obtained.

##### **b. Mailings to patients, clinicians, support groups – completed**

Patients receiving their oncologic care at the Seattle Cancer Care Alliance, and their support groups and care providers were mailed informational materials just prior to when the trial opened to accrual in June 2001. Since then, patients have been approached for recruitment at the time they come in for their clinical follow-up.

#### **Task 2: Subject Recruitment - ongoing**

As of June 2002, 631 breast cancer patients had been screened through the Seattle Cancer Care Alliance. We received 56 additional self or clinician referrals. From both groups, 467 were found to be ineligible, 52 refused participation. The number one reason for ineligibility at our institution is stage (75%). Of the eight women who stated their primary reason for refusal, the most common reasons have been complaints of invasiveness of the trial (15%) and unwillingness to take phytoestrogen supplements (31%). Surprisingly, refusal to take isoflavone tablets has been more of a deterrent to participation than the breast biopsy so far. This has been due to a fear of stimulation of recurrence, as well as an unwillingness to be randomized to active vs. placebo tablets

because of either strong desire for active tablet (unacceptance of placebo control) or preference for a dietary intervention.

At the first meeting of the Data Safety Monitoring Committee in December 2001, it was determined that we were behind accrual goals. In order to increase recruitment yield, the investigators have agreed to relax the stage eligibility criteria to include women with Stage IIB breast cancer, as long as fewer than 4 lymph nodes were involved. A mechanism to see patients who receive their oncologic care outside the sponsoring institution was also subsequently developed, and a community outreach campaign begun. In the past month, 4 more women have been randomized.

In a formal analysis comparing of clinic and community based recruitment in the first year of the trial, we found that community based recruitment has yielded more participants. Specifically, 41 eligible women were identified through the clinic over 12 months. However, 80% of those who are currently eligible refused participation. On the other hand, community based recruitment has yielded 25 eligible women over 6 months, and those who were eligible were 15 times more likely to participate. This analysis was presented at the American Institute for Cancer Research meeting in June (see Reportable Outcomes section).

#### Task 3: Clinical Trial - ongoing

Of the 14 subjects randomized, none have reported side effects attributable to the isoflavone tablets. One woman developed a small post biopsy hematoma, and 2 complained of the dressings used, but the others have not complained of significant discomfort with their breast biopsies. Blood collections for serum hormone evaluations at baseline, 6 months, and one year are ongoing. Serum is aliquotted and frozen at -70C within 8 hours of blood collection.

#### Task 4: Study Follow-up – scheduled to begin next year

Of the 14 randomized subjects, two have entered this phase of the study so far.

#### Task 5: Evaluation of Clinical Materials – scheduled to begin next year

Of the 14 randomized subjects, we expect to have full data on 8 subjects and mid-intervention data on the remaining 6 by the time of the next annual report. With the addition of community based recruitment, we expect to have 60 subjects randomized by June 2003.

#### Task 6: Data Analysis and Report Writing – scheduled for year #3

#### Key Research Accomplishments:

- Conduct of a breast chemoprevention trial with histologic endpoints requiring breast biopsy appears feasible.
- Community-based recruitment is proving more effective than clinic-based recruitment
- Isoflavone tablets and breast biopsies are well tolerated by participating subjects thus far.

### **Reportable Outcomes:**

Palomares MR and Gralow JR. "The Effect of Phytoestrogens on Normal Breast Tissue in Postmenopausal Breast Cancer Survivors: An Ongoing Trial," Proceedings of the AICR / WCRF International Research Conference on Food, Nutrition and Cancer, 2002.

### **Conclusions:**

We await years #2 and 3 of the study to address the proposal's specific aim of determining if changes in estrogen, androgen, and sex hormone binding globulin levels after 6 and 12 months of isoflavone intervention are significantly different from placebo.

### **References:**

- Adams JB. Adrenal androgens and human breast cancer: a new appraisal. *Breast Cancer Res Treat* 1998 Sep;51(2):183-188.
- Arnot, R. *The Breast Cancer Prevention Diet: The Powerful Foods, Supplements, and Drugs That Can Save Your Life*; Little Brown and Company: New York, 1998.
- Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. *Obstet Gynecol* 1998;91(1):6-11.
- Brzcinski A. Short term effects of phytoestrogen-rich diet on postmenopausal women. *Menopause*, 1997; 4:89-94.
- Canley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. *Ann Intern Med* 1999;130(4 Pt 1): 270-277.
- Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. *Environ Health Perspect* 1997 Apr;105 Suppl 3:583-585.
- Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. *J Clin Endocrinol Metab* 1999; 84(10): 3479-3484.
- Helferich WG. Paradoxical effects of the soy phytoestrogen genistein on growth of human breast cancer cells in vitro and in vivo. *Am J of Clin Nutr* 1998; 68(6S): 1524S-1525S.
- Knight DC, Eden JA. A review of the clinical effect of phytoestrogens. *Obstet Gynecol* 1996; 87:897-904.
- Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. *Cancer Epidemiol Biomarkers Prev* 1996;5:63-70.
- Helferich WG. Paradoxical effects of the soy phytoestrogen genistein on growth of human breast cancer cells in vitro and in vivo. *Am J of Clin Nutr* 1998; 68(6S): 1524S-1525S.
- Ingram D, Sanders K, Kolybaba M, Lopcz D. Case-control study of phyto-oestrogens and breast cancer. *Lancet* 1997;350: 990-994.

- Kerzer MS and Xu X. Dietary phytoestrogens. *Annu Rev Nutr*, 1997; 17:353-381.
- Kodama M, Kodama I, Miura S, Yoshida. Nutrition and breast cancer risk in Japan. *Anticancer Res*, 1991; 11: 745-754.
- Lee H, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast cancer risk in Singapore. *Lancet* 1991;337(8751):1197-1200.
- McMichael-Phillips DF, Harding C, Morton M, Roberts SA, Howell A, Potten CS, Bundred NJ. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. *Am J Clin Nutr* 1998;68(6 Suppl):1431S-1435S.
- Mcsiano S, Katz SL, Lee JY, Jaffe RB. Phytoestrogens alter adrenocortical function: genistein and daidzein suppress glucocorticoid and stimulate androgen production by cultured adrenal cortical cells. *J Clin Endocrinol Metab* 1999; 84(7): 2443-2448.
- Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. *Nutrition and Cancer* 1994; 21(2): 113-131.
- Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. *Maturitas* 1995;21(3):189-195.
- O'Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. *Br J Cancer* 1987; 56(5): 601-604.
- Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Mike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 1996;5(10):785-794.
- Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. *Am J Clin Nutr*, 1998; 68 (6 Suppl):133S-1346S.
- Setchell KD and A Cassidy. Dietary isoflavones: biological effects and relevance to human health. *J Nutr*, 1999; 129:758S-767S.
- Shoff SM, Newcomb PA, Mares-Perlman JA, Klein BE, Haffner SM, Storer BE, Klein R. Usual consumption of plant foods containing phytoestrogens and sex hormone levels in postmenopausal women in Wisconsin. *Nutr Cancer* 1998;30(3):207-212.
- Stanford JL, Herrington LJ, Schwartz SM, Weiss NS. Breast cancer incidence in Asian migrants to the United States and their descendents. *Epidemiology*, 1995; 13: 287-295.
- Soderqvist, G. Effects of sex steroids on proliferation in normal mammary tissue. *Ann Med* 1998; 30(6): 511-524.
- Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. *Cancer Causes Control* 1997; 8(6): 922-8.
- Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. *Proc Soc Exp Biol Med*, 1995; 208:124-130.
- Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, Pasternack BS, Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. *Am J Epidemiol* 1997; 145(11): 1030-8.

## **THE EFFECT OF PHYTOESTROGENS ON NORMAL BREAST TISSUE IN POSTMENOPAUSAL BREAST CANCER SURVIVORS**

Melanie R. Palomares, MD and Julie R. Gralow, MD

Phytoestrogens have received media attention as a form of breast cancer prevention. Although epidemiologic studies support this claim, there are no prospective clinical trials demonstrating such a protective effect. This project, supported by an AICR Postdoctoral Award, aims to evaluate the effect of a phytoestrogen supplement on the breast tissue of postmenopausal breast cancer survivors. Sixty disease-free, post-therapy, postmenopausal women with in-situ or early invasive (St. 0-II) breast cancer are to be randomized to either 100mg/d isoflavone tablets or placebo for one year. Biopsies of the uninvolved breast are examined for proliferative changes in response to phytoestrogens, as well as immunohistochemical breast cancer biomarkers. Mammography is performed to assess breast density, and for close monitoring for recurrence. As secondary endpoints, menopausal symptoms, vaginal epithelial changes, endometrial histology, and serum steroid hormones are also being measured.

The trial was opened to accrual in June 2001. Since then, 631 breast cancer patients have been screened through the Seattle Cancer Care Alliance. We received 56 additional self or clinician referrals. From both groups, 467 were found to be ineligible, 52 refused participation, and 14 have consented to participate so far. The number one reason for ineligibility at our institution is stage (75%). Of the eight women who stated their primary reason for refusal, the most common reasons have been complaints of invasiveness of the trial (15%) and unwillingness to take phytoestrogen supplements (31%). Of the 10 women actually enrolled in the study, none have reported side effects attributable to the isoflavone tablets. One woman developed a small post biopsy hematoma, and 2 complained of the dressings used, but the others have not complained of significant discomfort with their breast biopsies.

In order to increase recruitment yield, a mechanism to see patients who receive their oncologic care outside the sponsoring institution has been developed, and a community outreach and education campaign regarding phytoestrogens begun. Mammographic density will be followed to see if it can serve as a noninvasive endpoint for breast epithelial proliferation.